During the past half century, research on neuropsychiatric disorders such as schizophrenia, mood disorder, and dementia has mainly focused on neurotransmitters such as serotonin, dopamine, and acetylcholine. However, immune dysfunctions have recently been considered another important factor in the etiology and pathophysiology of these disorders. The involvement of immune system activation in the pathophysiology of certain psychiatric disorders is well documented. Increased tryptophan degradation induces serotonin depletion and depressive mood. Conversely, the downstream metabolites from this pathway, including 3-hydroxykynurenine, quinolinic acid, and kynurenic acid, are neuroactive metabolites that can modulate several neurotransmissions, such as glutamatergic, GABAergic, dopaminergic, and noradrenergic neurotransmissions, which in turn induce changes in the neuronal-glial network and neuropsychiatric consequences. Investigations regarding glial functions have provided increasing evidence indicating that glial cells perform important roles in various brain functions. Discovering glial functions and further understanding these crucial cells, as well as the interaction between neurons and glia may aid in clarifying many unknown aspects including the mind-brain gap and conscious-unconscious relationships. Central nervous system (CNS) inflammation and immune activation play a major role in the pathophysiology of neuropsychiatric disorders. A better understanding of the interaction between inflammatory mediators, such as cytokines, and the activated immune response, including astrocytes and microglia, is critical for the development of new therapeutic strategies for neuropsychiatric disorders.

In this special issue, the relationship between glia-neuron and cytokines in the pathophysiology of neuropsychiatric disorders and the action mechanisms of drugs used for their treatment are reviewed. Evidence is provided for the role of inflammation-induced toxic metabolites from the tryptophan pathway in neuropsychiatric disorders such as depression, bipolar disorder, and Alzheimer\'s disease (AD). A better understanding of the interactions between cytokines, glia, and neurons provides new strategies for the development of novel therapeutic targets for neuropsychiatric disorders.

Pinto *et al*. focused on neuron-glia interactions and their role in the pathophysiology and treatment of bipolar disorder. Both postmortem and *in vivo* studies showed that microglial activation is involved in the neurobiology of bipolar disorder, which is in agreement with the presence of peripheral inflammatory markers described in meta-analyses and the blood-brain barrier (BBB) disruption hypothesis. Furthermore, neuroimaging studies support the presence of abnormalities in the microstructure of white matter, indicating the involvement of oligodendrocytes. In addition, changes in inflammatory markers and microglial function may play an important role in neuroprogression in bipolar disorder. Several drugs used in the treatment of bipolar disorder have effects on glial cells, and future studies may use these cells as targets for the development of new treatments.

Kim and Jeon focused on how the immune system can cause imbalances in the kynurenine pathway, which ultimately leads to anxiety disorders. Accumulating evidence has indicated the modulatory effects of the immune-kynurenine pathway on anxiety. The tryptophan catabolites (TRYCATs) in the kynurenine pathway imbalanced by stress or inflammation induce serotonin and melatonin deficiencies, increasing the sensitivity of anxiety reactions. In addition, TRYCATs cause or sustain anxiety by acting as endogenous anxiogens or anxiolytics, an NMDA agonist or antagonist, or a free radical generator. In future, additional human studies should be conducted based on this evidence, which could be used in the development of new therapies for the treatment of anxiety disorders.

Fakhoury reviewed the mechanisms of immune reaction and neuroinflammation in AD, with an emphasis on the function of genes associated with a risk of AD in terms of neuroinflammation and immune function. While several studies have indicated that glial activation prevents the progression of AD by facilitating the clearance of amyloid β (Aβ) in the brain, other studies have shown that impaired or exacerbated glial activation increases the production of proinflammatory cytokines and Aβ in the brain. This duality in the effects of glial-mediated inflammation on the progression of AD-related pathologies has encouraged investigators to explore different and sometimes opposing strategies for the treatment of AD. Future studies should continue to characterize the mechanisms of glial-mediated inflammation in AD, including potential cross-talk between different cellular signaling.

Felger clarified the neuroimaging effects of inflammation on reward and threat circuitry in mood and anxiety-related disorders. Their review presents evidence that peripheral inflammation can affect brain regions relevant to reward and threat sensitivity, leading to the symptoms of reduced motivation, motor slowing, and anxiety. Biomarkers of inflammation such as inflammatory cytokines and acute-phase proteins are typically elevated in a significant proportion of patients with major depression, bipolar disorder, anxiety disorders, or post-traumatic stress disorder (PTSD) and may be a factor in behavioral symptoms. Neuroimaging studies showed that the effects of inflammation on reward and threat circuitry may be used as biomarkers of inflammation for future development of novel therapeutic strategies for better treatment of mood and anxiety-related disorders in patients with high inflammation.

Kim and Shin reviewed the gut-microbiota-brain axis in neuropsychiatric disorders and its pathophysiological mechanisms and novel treatments. The bidirectional interaction between microorganisms and the brain affects various CNS activities (such as stress response, behavior, and mood) through immune and neuroendocrine system pathways. Apparently, the gut microbiota directly or indirectly affects neuropsychiatric illness. Diverse forms of neuropsychiatric disorders (*i.e*., autism, depression, anxiety, and schizophrenia) are associated with or modulated by variations in the microbiome, microbial substrates, and exogenous prebiotics, antibiotics, and probiotics. The microbiota--gut--brain axis might provide novel targets for prevention and treatment of neuropsychiatric disorders.

Orsolini *et al*. presented a systematic review of the critical role of the acute inflammatory phase protein C-reactive protein (CRP) in schizophrenia. Study results showed elevated CRP levels in schizophrenia, mainly correlated with the severity of illness and during the recrudescent phase. CRP levels are higher when catatonic features, negative symptomatology, and aggressiveness are involved. Apparently, CRP levels are not related to suicidal behavior and ideation. Whether the inflammation is a by-product of the pathophysiology of schizophrenia or directly contributes to the clinical manifestations of schizophrenia remains unclear, although the results support the hypothesis that CRP and its blood levels are potential biomarkers in schizophrenia.

In the present review, the role of inflammation in the pathophysiology and treatment of neuropsychiatric disorders is evaluated. Although ample data support the "inflammation hypothesis" of mental disorders, many unanswered questions and controversies remain. For example, many studies have reported that inflammatory mediator levels are not altered among mentally-ill patients; however, the vast majority of data obtained from human studies examining peripheral tissues (especially blood) showed that data on brain tissue is more pertinent to the study of psychiatric illnesses. How the effects of psychotropic drugs on inflammation influence their therapeutic efficacy and toxicity is not well understood. Several studies have revealed negative results regarding the effectiveness of anti-inflammatory compounds as a treatment for mental disorders. Hopefully, the existing knowledge will be expanded and unresolved questions answered regarding this subject.
